Similarly, Cummings et al. reported that suppression of ERCC1, a gene involved in both nucleotide excision repair (NER) and homologous recombination repair, sensitizes prostate cancer cells to both mitomycin C and cisplatin while inhibition of XPA, which is only involved in NER, only sensitizes the cells to cisplatin [25]. Here, XPA is linked to Familial prostate cancer.